Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Keryx Biopharmaceuticals Inc (NASDAQ:KERX)

6.68
Delayed Data
As of 3:59pm ET
 +0.01 / +0.15%
Today’s Change
4.11
Today|||52-Week Range
8.38
+13.99%
Year-to-Date

Five Year Financial Summary

Total Revenue

Cash & Short Term Investments

Cash From Operations

All Currency in US Dollars4 Quarter
Trend
Quarter 3
2016
Quarter 4
2016
Quarter 1
2017
Quarter 2
2017
Revenue and IncomeNet Revenues6.3M9.5M11.8M15.1M
 
 
 
 
 
Cost of Goods Sold19.0M26.0M5.1M5.0M
 
 
 
 
 
Depreciation And Amortization256.0K229.0K229.0K230.0K
 
 
 
 
 
 
Operating ExpensesGross Income-12.9M-16.7M6.5M9.9M
 
 
 
 
 
General Expenses28.9M29.0M29.6M33.8M
 
 
 
 
 
Other Operating Expenses0.00-11.8M0.000.00
 
 
Research And Development8.7M6.2M6.8M9.0M
 
 
 
 
 
Total Operating Expenses48.2M43.4M34.9M39.0M
 
 
 
 
 
 
Non-Operating ExpensesOperating Income-41.8M-33.9M-23.1M-23.9M
 
 
 
 
 
Extraordinary Credit0.000.000.00225.0K
 
 
Interest Expense On Debt0.00--0.0063.0M
 
 
Other Expenses-19.0K1.0K-3.0K-5.0K
 
 
 
 
 
 
Income Taxes, Minority Interest and Extra ItemsPre-Tax Income-41.7M-33.8M-23.0M-86.5M
 
 
 
 
 
Income Taxes-20.0K-20.0K-20.0K-20.0K
 
 
 
 
 
Net Income-41.7M-33.8M-23.0M-86.5M
 
 
 
 
 
 
Shares To Calculate EPSShares To Calculate EPS105.9M106.0M107.1M112.6M
 
 
 
 
 
Shares To Calculate EPS Diluted105.9M106.0M107.1M112.6M
 
 
 
 
 
 
Earnings Per ShareEPS-$0.39-$0.32-$0.21-$0.77
 
 
 
 
 
EPS Diluted-$0.39-$0.32-$0.21-$0.77